LXR agonists lead to IDOL-mediated degradation of the low-density lipoprotein receptor (LDLR) and increase the expression of the ABCA1 cholesterol efflux transporter, and this axis may be used as a potential drug target in multiple cancers, while the LXR/ABCA1 axis also emerges as a promising drug target in cancer therapy by reducing cholesterol levels [114]. Here, LDLR is linked to cancer.